Abstract 430P
Background
Teenagers and young adults (age 15-29) are increasingly the focus of cancer care in India. Young persons from rural western Madhya Pradesh, a resource crunch area, need provided support, and a care pathway to ensure optimal results in the treatment of cancer.
Methods
Disease characteristics of TYA patients over (30 months) from 2018-thru 2020 were analyzed. Abandonment defined as. Failure to start / complete treatment was quantified, and the cancers were documented by the Birch classification. Early deaths (within 30 days) and trends to completion of therapy were documented. Telephonic tracing of patients, escorting them to hospital, providing accommodation, food caregiver support. Since Feb 2019, the state sponsored Insurance scheme Ayushman Bharat provided TYAs access to cancer care.
Results
Two hundred and forty six cancer patients’ records in the age group 15-29 years were. analysed in a retrospective study. Median age 23 years; M: F 166: 80. Diseases were classified by the Birch Classification: Leukemias 84; Lymphomas. 45; Brain 6; Bone tumors 55; Soft tissue tumors 6; Germ Cell tumors 19; Carcinoma 30; Miscellaneous 1; Twenty two (9%) abandoned treatment. 65 (26%) alive after completed therapy; Early deaths occurred in 56 (23%); as of 30 June 2020, 103 (41%) are alive on treatment.
Conclusions
Early deaths occurred on account of poor nutrition; delayed diagnosis; toxicity of therapy.TYAcan Foundation provided diagnostic, treatment and accommodation support; mitigating early morbidity and mortality; tracking young persons to reduce abandonment. Early trends indicate that the government Ayushman Scheme and the social entrepreneurship of TYAcan together helped establish a viable care pathway for young cancer patients to achieve to survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Medical Oncology, Sri Aurobindo Institute of Medical sciences.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session